Terremoto Biosciences Raises $108 Million in Series C Financing

Funds will advance selective AKT1 inhibitors for cancer and rare diseases

Apr. 15, 2026 at 3:39pm

Got story updates? Submit your updates here. ›

A high-end, photorealistic studio still-life photograph featuring a group of polished metal and glass laboratory equipment, including beakers, pipettes, and test tubes, arranged elegantly on a clean, white seamless background. The objects are lit with dramatic studio lighting, creating deep shadows and highlighting the premium materials.Terremoto Biosciences' $108 million Series C financing will fund the clinical advancement of its innovative AKT1-targeted cancer and rare disease therapies.South San Francisco Today

Terremoto Biosciences, a biotechnology company developing targeted small molecule medicines, has closed a $108 million Series C financing round. The funding will enable the company to advance its lead AKT1-selective inhibitor programs through Phase 1 clinical development for patients with cancer and the rare disease hereditary hemorrhagic telangiectasia.

Why it matters

The successful Series C financing demonstrates investor confidence in Terremoto's pipeline of AKT1-targeted therapies, which have the potential to address unmet needs in oncology and rare diseases. AKT1 is a key signaling protein implicated in many cancers, making it an attractive therapeutic target.

The details

The Series C round was led by new investors RA Capital Management, Deep Track Capital, Osage University Partners (OUP), and BeOne Medicines, alongside Terremoto's existing investors. The proceeds will fund the clinical development of Terremoto's lead AKT1-selective inhibitor candidates.

  • The financing was closed on April 15, 2026.

The players

Terremoto Biosciences

A biotechnology company developing targeted small molecule medicines, including AKT1-selective inhibitors for cancer and rare diseases.

RA Capital Management

A new investor that participated in Terremoto's Series C financing round.

Deep Track Capital

A new investor that participated in Terremoto's Series C financing round.

Osage University Partners (OUP)

A new investor that participated in Terremoto's Series C financing round.

BeOne Medicines

A new investor that participated in Terremoto's Series C financing round.

Got photos? Submit your photos here. ›

What’s next

Terremoto plans to initiate Phase 1 clinical trials for its lead AKT1-selective inhibitor candidates in the coming months.

The takeaway

Terremoto's successful Series C financing round underscores the promise of its AKT1-targeted therapies and the company's ability to attract significant investment to advance its pipeline of innovative cancer and rare disease treatments.